NYSE - Nasdaq Real Time Price USD

Elanco Animal Health Incorporated (ELAN)

12.94
+0.06
+(0.47%)
At close: 4:00:02 PM EDT
12.94
-0.02
(-0.12%)
After hours: 4:09:39 PM EDT
Loading Chart for ELAN
  • Previous Close 12.88
  • Open 12.75
  • Bid 12.90 x 1000
  • Ask 12.91 x 2200
  • Day's Range 12.67 - 12.99
  • 52 Week Range 8.02 - 18.80
  • Volume 4,297,877
  • Avg. Volume 5,680,796
  • Market Cap (intraday) 6.427B
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) 17.25
  • EPS (TTM) 0.75
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.18

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

www.elanco.com

9,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ELAN

View More

Performance Overview: ELAN

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ELAN
6.85%
S&P 500 (^GSPC)
0.60%

1-Year Return

ELAN
24.06%
S&P 500 (^GSPC)
11.47%

3-Year Return

ELAN
41.89%
S&P 500 (^GSPC)
47.05%

5-Year Return

ELAN
32.32%
S&P 500 (^GSPC)
106.62%

Compare To: ELAN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ELAN

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    6.40B

  • Enterprise Value

    10.30B

  • Trailing P/E

    17.17

  • Forward P/E

    15.15

  • PEG Ratio (5yr expected)

    6.31

  • Price/Sales (ttm)

    1.45

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    2.33

  • Enterprise Value/EBITDA

    7.35

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.43%

  • Return on Assets (ttm)

    1.14%

  • Return on Equity (ttm)

    6.01%

  • Revenue (ttm)

    4.43B

  • Net Income Avi to Common (ttm)

    373M

  • Diluted EPS (ttm)

    0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    487M

  • Total Debt/Equity (mrq)

    69.18%

  • Levered Free Cash Flow (ttm)

    1.32B

Research Analysis: ELAN

View More

Company Insights: ELAN

Research Reports: ELAN

View More

People Also Watch